On June 22, 2026, Sagimet Biosciences Inc., listed on Nasdaq as SGMT, based in San Mateo, California, revealed plans for its involvement in 1x1 investor meetings at the Leerink Partners Therapeutics Forum in Boston, MA on July 15, 2026. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical firm specializing in developing innovative treatments that target dysfunctional metabolic and fibrotic pathways.